Gufic BioSciences Ltd
₹ 200
-4.69%
30 May
- close price
About
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Key Points
- Market Cap ₹ 1,942 Cr.
- Current Price ₹ 200
- High / Low ₹ 243 / 177
- Stock P/E 24.4
- Book Value ₹ 35.9
- Dividend Yield 0.05 %
- ROCE 22.6 %
- ROE 25.8 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 38.6% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.3%
- Company's median sales growth is 22.5% of last 10 years
Cons
- Company might be capitalizing the interest cost
- Working capital days have increased from 91.2 days to 136 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
81 | 98 | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | |
74 | 87 | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 633 | 556 | |
Operating Profit | 7 | 11 | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 146 | 135 |
OPM % | 9% | 11% | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% |
0 | 0 | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | |
Interest | 3 | 4 | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 |
Depreciation | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 17 | 22 |
Profit before tax | 3 | 5 | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 |
Tax % | 49% | 37% | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% |
Net Profit | 2 | 3 | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 |
EPS in Rs | 0.20 | 0.43 | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 |
Dividend Payout % | 25% | 12% | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% |
Compounded Sales Growth | |
---|---|
10 Years: | 22% |
5 Years: | 18% |
3 Years: | 22% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | 37% |
5 Years: | 39% |
3 Years: | 52% |
TTM: | -17% |
Stock Price CAGR | |
---|---|
10 Years: | 43% |
5 Years: | 8% |
3 Years: | 56% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 30% |
5 Years: | 31% |
3 Years: | 32% |
Last Year: | 26% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | |
Reserves | 12 | 15 | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 |
20 | 35 | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | |
34 | 32 | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | |
Total Liabilities | 74 | 90 | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 |
18 | 27 | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | |
CWIP | 1 | 3 | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
55 | 60 | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | |
Total Assets | 74 | 90 | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 5 | 11 | 11 | -4 | -4 | -5 | 5 | 47 | 87 | 104 | ||
-3 | -13 | -3 | -2 | -1 | -5 | -9 | -13 | -43 | -7 | -96 | ||
-2 | 8 | -7 | -5 | 5 | 7 | 14 | 8 | -4 | -79 | -3 | ||
Net Cash Flow | 0 | 0 | 1 | 4 | -0 | -1 | 1 | -0 | 0 | 2 | 5 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 101 | 75 | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 |
Inventory Days | 137 | 143 | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 |
Days Payable | 180 | 144 | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 |
Cash Conversion Cycle | 58 | 74 | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 |
Working Capital Days | 82 | 71 | 64 | 48 | 76 | 84 | 109 | 128 | 110 | 80 | 58 | 136 |
ROCE % | 15% | 18% | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 7h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9h - Press release being issued by the Company on the captioned subject, the contents of which is self-explanatory. The same is submitted for public dissemination and …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9h - The Company has cleared the physical audit of The Brazilian Health Regulatory Agency (ANVISA) successfully without any observation. The Company has received Good Manufacturing Practices …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Investor Presentation on Audited Financial Results of the Company for the quarter and financial year ended March 31, 2023
- Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023 1d
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptNotesPPT
History[1]
Gufic was in the business of manufacturing and marketing injectable products since late 1970s. The group had earlier exited its API and formulations manufacturing division by selling its six major brands such as Mox (Amoxycillin) Injection, Zole (Miconazole Nitrate) etc. to Ranbaxy in 1997. The promoters then re-entered pharmaceutical formulations segment through incorporation of Gufic Biosciences Limited in 2000.
Gufic Biosciences has been manufacturing lyophilized injectables (their main business) for 40+ years. It started with small base of 50,000 vials back in 2007-08 to right now almost 4 million vials per month.